Collectively, therefore, our data support the utility of exploiting ES-62 to dissect the mechanisms regulating inflammatory networks and the potential of MyD88 as a target for therapeutic intervention in the differential (receptor-, inflammation site- and subtype-specific-) pathogenic mast cell responses associated with allergy. The gene discussed is MYD88; the disease is Allergy.